A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy
CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma
Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness
HIV immune evasion Nef enhances allogeneic CAR T cell potency. Perica K, Kotchetkov I, Mansilla-Soto J, Ehrich F, Herrera K, Shi Y, Dobrin A, Gonen M, Sadelain M. Nature 2025; 640(8059):793-801
— 2025cited by 0position: selected
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction
Engineering immune-evasive allogeneic cellular immunotherapies
Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies
Targeting HLA-E-overexpressing cancers with a NKG2A/C switch receptor
Author Correction: Senolytic CAR T cells reverse senescence-associated pathologies
Synthetic dual costimulation increases the potency of HIT and TCR targeted cell therapies. Dobrin A, Lindenbergh PL, Shi Y, Perica K, Xie H, Jain N, Chow A, Wolchok JD, Merghoub T, Sadelain M, Hamieh M. Nature Cancer 2024; 5(5):760-773
— 2024cited by 0position: selected
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, Carrasco SE, Nnuji-John E, Feucht J, Hinterleitner C, Barthet VJA, Boyer JA, Mezzadra R, Wereski MG, Tuveson DA, Levine RL,
— 2024cited by 0position: selected
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
CD19 CAR antigen engagement mechanisms and affinity tuning
Novel extragenic genomic safe harbors for precise therapeutic T cell engineering
CD19 CAR antigen engagement mechanisms and affinity tuning. He C, Mansilla-Soto J, Khanra N, Hamieh M, Bustos V, Paquette AJ, Garcia Angus A, Shore DM, Rice WJ, Khelashvili G, Sadelain M, Meyerson JR. Science Immunology 2023; 8(81):eadf1426
— 2023cited by 0position: selected
TET2 guards against unchecked BATF3-induced CAR T cell expansion. Jain N, Zhao Z, Feucht J, Koche R, Iyer A, Dobrin A, Mansilla-Soto J, Yang J, Zhan Y, Lopez M, Gunset G, Sadelain M. Nature 2023; 615(7951):315-322
— 2023cited by 0position: selected
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating. Hamieh M, Mansilla-Soto J, Rivière I, Sadelain M. Cancer Discovery 2023; 13(4):829-843
— 2023cited by 0position: selected
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer
HLA-independent T cell receptors for targeting tumors with low antigen density
The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer
HLA-independent T cell receptors for targeting tumors with low antigen density. Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, Zucchetti AE, Li Z, Sjöstrand M, Lindenbergh PL, Saetersmoen M, Dobrin A, Maurin M, Iyer A, Garcia Angus A, Miele MM, Zhao Z, Giavridis T, van der Steg
— 2022cited by 0position: selected
Generation of T cell receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Van der Stegen S, Lindenbergh PL, Petrovic RM, Xie H, Diop MP, Alexeeva V, Shi Y, Mansilla-Soto J, Hamieh M, Eyquem J, Cabriolu A, Wang X, Abujarour R, Lee T, Clarke R, Valamehr B, T
— 2022cited by 0position: selected
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Nature Rev Immunol 2022; 22(92):85-96
— 2022cited by 0position: selected
Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
Senolytic CAR T cells reverse senescence-associated pathologies
Senolytic CAR T Cells Reverse Senescence-Associated Pathologies. Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, Mansilla-Soto J, Boyer JA, Li X, Giavridis T, Kulick A, Houlihan S, Peerschke E, Friedman SL, Ponomarev V, Piersigilli A, Sadelain M, Lowe SW. Nature 2020; 583(7814):127-132
— 2020cited by 0position: selected
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL